Investigational agents. STI571 has already been approved for the treatment of chronic myelogenous leukemia (CML). Other agents are in a preclinical or in a early clinical phase.
| - Proteine tyrosine kinase inhibitors | - STI571 (Gleevec) |
| - Other | |
| - Ras inhibitors | - Farnesyl transferase inhibitors |
| - Other | |
| - Other signal transduction inhibitors | |
| - Proteasome inhibitors | |
| - Histone deacetylase inhibitors | |
| - Vaccines (e.g. protein, pulsed dendritic cells) | |
| - Proteine tyrosine kinase inhibitors | - STI571 (Gleevec) |
| - Other | |
| - Ras inhibitors | - Farnesyl transferase inhibitors |
| - Other | |
| - Other signal transduction inhibitors | |
| - Proteasome inhibitors | |
| - Histone deacetylase inhibitors | |
| - Vaccines (e.g. protein, pulsed dendritic cells) | |